Mainz Biomed to Present Blood-Based mRNA Biomarker Data at Digestive Disease Week 2026 Pancreatic Cancer Session

Reuters
02/24
Mainz Biomed to Present Blood-Based mRNA Biomarker Data at Digestive Disease Week 2026 Pancreatic Cancer Session

Mainz Biomed N.V. will attend Digestive Disease Week (DDW) 2026 in Chicago, Illinois, where it will present a poster in the pancreatic cancer session titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS.” The document does not provide the date of the event. https://www.globenewswire.com/Tracker?data=TbT19reQLLE5OLJ3Os0dj3ICnSkrrrRWe7mI8FDLlgh7HzuFQuQTc01KWGDBybmAEscRfZSUgR05C9te3vByHpdkHLihTmqW0bSdwBg02JOvwJSsguzRkvE9tEfcUf4lTgfOm5gVIiQG9uesOZS1104rArBLvnDZiHUD4TpLQJ6RUxxvareRL6fVMtUO4-bSHj3hs1eOTlC0T2u9t2ajxXRDXLgVwj_jqjDH_o_27N8= http://mainzbiomed.com/investors/

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602240730PRIMZONEFULLFEED1001166317) on February 24, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10